ArticleActa oncologica (Stockholm, Sweden)2024
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.
Article in Acta oncologica (Stockholm, Sweden), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Genomic Medicine Sweden: Advancing precision medicine at the national level.Journal of internal medicine · 2026Review
- Assessing clinical decision support system tools in precision oncology: piloting ring testing.ESMO real world data and digital oncology · 2026Article
- Article
- FOCU.SE trial: a nationwide Swedish drug repurposing protocol and research framework.Acta oncologica (Stockholm, Sweden) · 2026Article
- Precision cancer medicine in Europe: a mixed-methods study on infrastructure for extended molecular diagnostics.Journal of cancer research and clinical oncology · 2026Article
- Merging clinical research and standard healthcare - Nordic Precision Cancer Medicine Symposium 2025.Acta oncologica (Stockholm, Sweden) · 2026Article
- 'Crossing borders' in data standardisation: application of OMOP CDM in an international clinical trial network in precision cancer medicine.Acta oncologica (Stockholm, Sweden) · 2026Article
- Realising precision oncology through shared real-world data infrastructure.Acta oncologica (Stockholm, Sweden) · 2026Article
- A conceptual health economic modelling framework to assess the cost-effectiveness of molecular target-driven treatment regimens in oncology.Acta oncologica (Stockholm, Sweden) · 2026Article
- Procedures of data merging in precision cancer medicine: the PRIME-ROSE project.Acta oncologica (Stockholm, Sweden) · 2026Article
- Accelerating precision oncology by converging pragmatic trials and real-world evidence.Nature reviews. Drug discovery · 2025Article
- Precision cancer medicine 2025: some concerns.Acta oncologica (Stockholm, Sweden) · 2025Article
- The promises of precision medicine - voices from the Nordics.Acta oncologica (Stockholm, Sweden) · 2025Article
- Feasibility and outcome of genomics-guided treatment selection in advanced cancer - the MEGALiT explorative clinical trial.Acta oncologica (Stockholm, Sweden) · 2025Article
- Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare.Acta oncologica (Stockholm, Sweden) · 2024Article
- Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful. PATIENTS AND
methodsPCM4EU and PRIME-ROSE gather 17 and 24 partners, respectively, from 19 European countries. The projects are based on a network of Drug Rediscovery Protocol (DRUP)-like clinical trials that are currently ongoing or soon to start in 11 different countries, and with more trials expected to be established soon. The main aims of both the projects are to improve implementation pathways from molecular diagnostics to treatment, and reimbursement of diagnostics and tumour-tailored therapies to provide examples of best practices for PCM in Europe.
resultsPCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024.
conclusionPCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024.
conclusionEuropean collaboration can facilitate the implementation of PCM and thereby provide affordable and equitable access to precision diagnostics and matched therapies for more patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.